We now know that the pathophysiology of various autoimmune diseases shows a greater degree of similarities and low-dose IL2 shows promising results in autoimmune diseases in general and, in various studies, is found to have a better safety profile as compared to standard therapy alone. Here, IL2 is linked to autoimmune disease.